Literature DB >> 10201992

In vivo selection of neutralization-resistant virus variants but no evidence of B cell tolerance in lymphocytic choriomeningitis virus carrier mice expressing a transgenic virus-neutralizing antibody.

P Seiler1, B M Senn, M A Bründler, R M Zinkernagel, H Hengartner, U Kalinke.   

Abstract

B cell tolerance is maintained by active deletion and functional anergy of self-reactive B cells depending on the time, amount, and site of the self-antigen expression. To study B cell tolerance toward a transplacentally transmitted viral Ag, we crossed transgenic mice expressing the mu heavy and the kappa light chain of the lymphocytic choriomeningitis virus (LCMV)-neutralizing mAb KL25 (HL25-transgenic mice) with persistently infected LCMV carrier mice. Although HL25-transgenic LCMV carrier mice exhibited the same high virus titers as nontransgenic LCMV carrier mice, no evidence for B cell tolerance was found. In contrast, enhanced LCMV-neutralizing Ab titers were measured that, however, did not clear the virus. Instead, LCMV isolates from different tissues turned out to be neutralization resistant Ab escape variants expressing different substitutions of amino acid Asn119 of the LCMV-glycoprotein 1 that displays the neutralizing B cell epitope. Virus variants with the same mutations were also selected in vitro in the presence of the transgenic mAb KL25 confirming that substitutions of Asn119 have been selected by LCMV-neutralizing Abs. Thus, despite abundant expression of viral neo-self-antigen in HL25-transgenic LCMV carrier mice, transgenic B cells expressing LCMV-neutralizing Abs were rather stimulated than tolerized and neutralization resistant Ab escape variants were selected in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10201992

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence.

Authors:  P Seiler; B M Senn; P Klenerman; U Kalinke; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Viral persistence in vivo through selection of neutralizing antibody-escape variants.

Authors:  A Ciurea; P Klenerman; L Hunziker; E Horvath; B M Senn; A F Ochsenbein; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

3.  Public versus personal serotypes of a viral quasispecies.

Authors:  Lukas Hunziker; Adrian Ciurea; Mike Recher; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-02       Impact factor: 11.205

4.  Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies.

Authors:  Lars Hangartner; Beatrice M Senn; Birgit Ledermann; Ulrich Kalinke; Peter Seiler; Etienne Bucher; Raphaël M Zellweger; Katja Fink; Bernhard Odermatt; Kurt Bürki; Rolf M Zinkernagel; Hans Hengartner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

5.  Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus.

Authors:  Bruno Eschli; Raphaël M Zellweger; Alexander Wepf; Karl S Lang; Katharina Quirin; Jacqueline Weber; Rolf M Zinkernagel; Hans Hengartner
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

6.  CD4 T cell responses in latent and chronic viral infections.

Authors:  Senta Walton; Sanja Mandaric; Annette Oxenius
Journal:  Front Immunol       Date:  2013-05-13       Impact factor: 7.561

7.  Adaptive immune defense prevents Bartonella persistence upon trans-placental transmission.

Authors:  Lena K Siewert; Christoph Dehio; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2022-05-17       Impact factor: 6.823

8.  Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread.

Authors:  Lars Hangartner; Raphaël M Zellweger; Mattia Giobbi; Jacqueline Weber; Bruno Eschli; Kathy D McCoy; Nicola Harris; Mike Recher; Rolf M Zinkernagel; Hans Hengartner
Journal:  J Exp Med       Date:  2006-07-31       Impact factor: 14.307

Review 9.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

Review 10.  Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases.

Authors:  Michela Flego; Alessandro Ascione; Maurizio Cianfriglia; Stefano Vella
Journal:  BMC Med       Date:  2013-01-04       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.